Treatments and outcomes in Chinese patients with serologically active clinically quiescent systemic lupus erythematosus: a retrospective observational study

Table 7 Multivariable logistic regressive analysis: risk factors for flare

	β	p	OR (95% CI)
SACQ patients	0.936	0.001	2.550 (1.478, 4.400)
Dose of corticosteroids^a (mg) when relapsed or at the end of follow-up	− 1.422	< 0.001	1.239 (1.102, 1.3914)
Taking antimalarials when relapsed or at the end of follow-up	− 1.039	< 0.001	0.241 (0.132, 0.442)
Taking immunosuppressants when relapsed or at the end of follow-up	− 0.945	< 0.001	0.354 (0.202, 0.619)

In both SACQ and SQCQ patients (85 patients). Variables included in the model: SACQ patients or not, age at diagnosis (years), dose of corticosteroids (mg) when relapsed or at the end of follow-up, taking antimalarials when relapsed or at the end of follow-up, taking immunosuppressants when relapsed or at the end of follow-up
^aCorticosteroid doses were converted to milligrams (mg) of prednisone equivalent

ISSN: 1478-6362